CONSORT 2010 Checklist for "Analgesic efficacy of nefopam for cancer pain: A randomized controlled study"

The efficacy of nefopam, a non-opioid, non-steroidal, central acting drug, for cancer pain remains unclear. We evaluated the analgesic efficacy of nefopam for cancer pain. Patients with moderate to severe cancer pain (n=40) were randomly divided into two groups. The nefopam group (n=20) received three 20 mg doses of nefopam every 8 hours. The placebo group (n=20) received normal saline. Intravenous patient-controlled analgesia with morphine was given for breakthrough pain for 48 hours. The primary outcome was significant pain reduction. Secondary outcomes were morphine consumption over 48 hours and incidence of side effects.

奈福泮（nefopam）作为一种非阿片类、非甾体类中枢作用药物，其用于癌痛的疗效仍不明确。本研究评估了奈福泮对癌痛的镇痛疗效。将40例中重度癌痛患者随机分为两组：奈福泮组（n=20）每8小时给予20mg奈福泮，共给药3次；安慰剂组（n=20）给予生理盐水。对于爆发痛，给予吗啡静脉患者自控镇痛，持续48小时。本研究的主要结局指标为疼痛显著缓解，次要结局指标为48小时内吗啡使用量及不良反应发生率。